Andrea Necchi, Associate Editor at Journal of Clinical Oncology, shared on X:
“I enjoyed a conversation with The Lancet Oncology Senior Editor Smriti Patodia on our latest findings from Sunrise4 trial (neoadjuvant TAR200+cetrelimab vs cetrelimab in pts with MIBC). Primary analysis with ctDNA/utDNA results are awaited.”
More from Andrea Necchi on OncoDaily.